EMA Authorised: Baiama (aflibercept) — Formycon AG

View source ↗

Summary

EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degeneration, macular edema, r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Baiama (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Retinal Vein Occlusion;Choroidal Neovascularization;Diabetes Complications. MAH: Formycon AG. Decision date: 06/11/2025